[PULM] Pulmatrix, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.62 Change: 0.02 (3.33%)

chart PULM

Refresh chart

Strongest Trends Summary For PULM

PULM is in the medium-term down -71% below S&P in 2 months.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities330 K Cash From Investing Activities-160 K Cash From Operating Activities-5.39 M Gross Profit
Net Profit-1.55 M Operating Profit-1.56 M Total Assets10.68 M Total Current Assets10.52 M
Total Current Liabilities640 K Total Debt Total Liabilities640 K Total Revenue
Technical Data
High 52 week4.39 Low 52 week0.3 Last close1 Last change15.72%
RSI30.94 Average true range0.34 Beta0.53 Volume15.04 K
Simple moving average 20 days-17.34% Simple moving average 50 days-55.27% Simple moving average 200 days-48.24%
Performance Data
Performance Week-2.42% Performance Month-54.76% Performance Quart-74.64% Performance Half182.12%
Performance Year-31.36% Performance Year-to-date-58.55% Volatility daily14.12% Volatility weekly31.58%
Volatility monthly64.73% Volatility yearly224.22% Relative Volume474.04% Average Volume1.02 M
New High New Low

News

2019-03-14 09:45:00 | Pulmatrix to Participate in Upcoming Investor Conferences

2019-03-12 12:22:00 | Pulmatrix Regains NASDAQ Compliance

2019-03-08 13:00:00 | These Four Tech Stocks Could Set The Pace On Friday

2019-02-19 09:00:00 | Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline

2019-02-12 09:30:00 | Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs

2019-02-08 07:00:00 | Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market

2019-02-07 09:00:00 | Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study

2019-02-06 12:15:00 | 4 Biotech Stocks Making Moves on Wednesday 2/6/19

2019-02-06 09:00:00 | Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1

2019-02-05 12:45:00 | Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split

2019-02-05 11:14:00 | Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock

2019-01-31 13:24:00 | Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock

2019-01-30 21:52:00 | Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock

2019-01-30 16:01:00 | Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock

2019-01-28 23:27:00 | Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock

2019-01-28 16:18:00 | Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock

2018-11-29 05:00:00 | Pulmatrix Announces $3.0 Million Registered Direct Offering

2018-11-21 09:30:00 | Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

2018-11-15 09:30:00 | Pulmatrix to Present Results from the Pulmazole PUR1900 Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

2018-11-14 16:30:00 | Pulmatrix Reports Q3 2018 Results

2018-09-18 11:45:57 | Who Owns Most Of Pulmatrix Inc NASDAQ:PULM?

2018-09-17 09:35:00 | Pulmatrix to present pre-clinical data on PUR1800 RV1162 at the European Respiratory Society International Congress

2018-08-28 10:00:00 | Pulmatrix to Present at the 20th Annual Rodman & Renshaw Global Investment Conference on September 5, 2018

2018-08-03 09:00:00 | Pulmatrix Reports Q2 2018 Results

2018-07-23 10:13:00 | Pulmatrix Announces the Formation of the Pulmazole Clinical Advisory Board to Support Future Development

2018-07-20 07:20:00 | Free Technical Research on Riot Blockchain and Three More Biotech Equities

2018-07-17 09:00:00 | Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

2018-06-25 08:30:00 | Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

2018-06-13 09:35:00 | Pulmatrix Announces Publication of Results from a Phase 1 Pharmacodynamic Study of PUR0200 in COPD Patients

2018-06-07 09:30:00 | Pulmatrix Announces Approval of Proposals Submitted to Company's Stockholders

2018-06-04 07:40:00 | Wired News - Madrigal Pharma Reported Encouraging Top-line Data at 36 Weeks from Phase-2 Clinical Trial of MGL-3196 in Patients with NASH

2018-06-04 07:20:00 | Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities

2018-05-25 12:49:31 | Interested In Pulmatrix Inc NASDAQ:PULM? Here’s How It Performed Recently

2018-05-17 09:35:00 | Pulmatrix selected to present company profile at the 2018 Respiratory Innovation Summit in San Diego

2018-05-11 09:00:00 | Pulmatrix Reports Q1 2018 Results

2018-03-29 00:02:00 | Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering

2018-03-13 16:42:00 | Pulmatrix Reports 2017 Financial Results; Provides 2018 Outlook on Pulmonary Disease Pipeline

2018-03-09 09:46:15 | Is Pulmatrix Inc NASDAQ:PULM A Financially Sound Company?

2018-02-12 09:35:00 | Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

2018-01-29 08:00:00 | Today’s Research Reports on Trending Tickers: Atossa Genetics and Pulmatrix

2018-01-28 23:01:36 | Is Pulmatrix Inc NASDAQ:PULM Undervalued?

2018-01-25 10:30:00 | PULM: MHRA Authorizes CTA; Patient Screening Commences!

2018-01-24 12:00:00 | Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018

2018-01-22 10:25:00 | Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole

2017-12-19 11:45:10 | How Pulmatrix Inc’s NASDAQ:PULM EPS Dropped 13.7%, Did Its Industry Show Weakness Too?

2017-12-04 17:10:12 | Pulmatrix Inc PULM: Time For A Financial Health Check

2017-11-29 08:47:45 | Pulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

2017-11-14 13:00:00 | PULM: Business And Financial Update For Third Quarter 2017

2017-11-09 16:30:00 | Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials

2017-10-31 11:00:00 | Pulmatrix Presents at the North American Cystic Fibrosis Conference